U.S. markets open in 7 hours 32 minutes

The Greater Cannabis Company, Inc. (GCAN)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0053-0.0001 (-1.85%)
At close: 3:53PM EDT

The Greater Cannabis Company, Inc.

15 Walker Avenue
Suite 101
Baltimore, MD 21208
United States
443 738 4051

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees2

Key Executives

NameTitlePayExercisedYear Born
Mr. Aitan ZacharinChairman, Pres, CEO, Acting CFO & Treasurer120kN/A1983
Mr. Mark Frederick RadomChief Legal Officer, VP & Gen. Counsel84kN/A1968
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


The Greater Cannabis Company, Inc., a biopharmaceutical company, focuses on the development and commercialization of technology for transmucosal delivery of legal medical or recreational cannabis and cannabinoids. The company's initial product is an oral transmucosal patch platform, which provides loaded actives to be absorbed by the buccal mucosa into the body. It intends to commercialize the technology by sublicensing or partnering with licensed producers, distributors, processors, consumer product, and pharmaceutical companies. The company was founded in 2014 and is based in Baltimore, Maryland.

Corporate Governance

The Greater Cannabis Company, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.